Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions.
Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma.
The company was incorporated in 2024 and is based in La Jolla, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Mark Paul Lappe |
Contact Details
Address: 11025 N. Torrey Pines Road, Suite 200 La Jolla, California 92037 United States | |
| Phone | (858) 795-4220 |
| Website | inhibrx.com |
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001739614 |
| CUSIP Number | 45720L107 |
| ISIN Number | US45720L1070 |
| Employer ID | 82-4257312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Founder, Chairman, President and Chief Executive Officer |
| Dr. Brendan P. Eckelman Ph.D. | Founder and Chief Scientific Officer |
| Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President and Chief Financial Officer |
| Quinn L. Deveraux | Founder |
| Dr. Ashraf Amanullah | Executive Vice President and Chief Technical Operations Officer |
| Leah Pollema J.D. | Vice President, Corporate Secretary and General Counsel |
| Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing and Commercial Planning |
| Jeffrey J. Jensen | Executive Vice President and Chief Clinical Operations Officer |
| David Matly M.B.A. | Executive Vice President and Chief Commercial and Business Development Officer |
| Dr. Carlos Bais Ph.D. | Executive Vice President of Translational Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | 15-12G | Securities registration termination |
| Jun 3, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 31, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 30, 2024 | POSASR | Filing |
| May 30, 2024 | 8-K | Current Report |
| May 30, 2024 | 25-NSE | Filing |